What Is GHRP-2?

1. How does GHRP-2 work?

GHRP-2 activates a receptor used by ghrelin, a hormone involved in appetite and growth hormone secretion. This signaling stimulates the pituitary gland to release GH. The Japanese pralmorelin label describes its action through the hypothalamus and pituitary, the brain’s hormone-control system.

GH affects tissues directly and influences production of insulin-like growth factor 1, or IGF-1. Researchers often measure both. They can move differently: a brief increase in GH does not guarantee a sustained increase in IGF-1.

HGH treatment supplies growth hormone itself. GHRP-2 supplies a signal to release it. Sermorelin and CJC-1295 stimulate another target, the growth hormone-releasing hormone receptor. These differences explain why the compounds are discussed together and why their study results are not interchangeable.

2. What do human GHRP-2 studies show?

The most useful studies for a healthy reader measured meals and hormone responses. Their small samples and short observation periods leave body-composition and long-term safety questions open.

These are direct human observations. None supplies a reliable number for muscle gained, waist reduction or days saved in injury rehabilitation.

3. GHRP-2 hunger and appetite

In the 2005 Laferrère study, every participant ate more during the GHRP-2 condition. Researchers used a subcutaneous infusion lasting 270 minutes and measured a freely chosen buffet meal. The approximately 36% increase describes food eaten under those conditions; it should not be read as a 36% increase in daily calories.

The 2006 follow-up found increased intake in both lean participants and participants with obesity. A larger experimental exposure produced a larger average meal response. GHRP-2 therefore has human evidence for stimulating eating, including in people who already carry excess weight.

For someone trying to maintain a calorie deficit, extra hunger could make adherence harder. For someone struggling to eat enough, appetite may sound attractive, but these experiments did not establish a safe long-term bulking treatment. More food can add fat as well as support training.

Adding GHRP-2 to semaglutide or tirzepatide also introduces competing appetite goals. The meal experiments did not test either combination, muscle preservation during GLP-1 treatment, or treatment of medication-related nausea.

4. Muscle growth, fat loss, sleep and recovery

GHRP-2 has biological activity. The unresolved issue for a lifter is whether repeated exposure produces a worthwhile change in performance or physique at an acceptable risk.

A before-and-after report becomes difficult to interpret when calories, training and other drugs change together. A higher body weight could reflect extra food, fluid or tissue growth. An IGF-1 result cannot tell those apart.

This also limits “results in four weeks” promises. An early hormone response gives no validated timetable for visible muscle growth or injury repair. Record the actual goal separately from the blood marker used to explain the mechanism.

5. Tolerance and the GH–IGF-1 gap

Nijland and colleagues found mean peak GH concentrations of 83, 59 and 51 micrograms per liter on days one, three and five. The response weakened significantly, although GH release continued. Mean IGF-1 did not rise over the five-day experiment.

That result challenges two assumptions: that the initial response will repeat unchanged, and that a large GH spike necessarily produces a higher average IGF-1 level. It does not prove permanent receptor damage or establish that every regimen loses effect on day five.

The study also did not test recovery after a break. It cannot validate an eight-week cycle, a weekend-off schedule or increasing the dose to counter a weaker response. Each would require its own benefit and safety evidence.

6. GHRP-2 vs GHRP-6, ipamorelin and hexarelin

Claims that GHRP-2 avoids hunger because GHRP-6 is the “hunger peptide” conflict with GHRP-2’s meal-study results. How hungry a particular person feels also cannot be predicted from the compound name alone.

Raun and colleagues’ ipamorelin paper tested hormone selectivity in pigs. That helps explain the distinction between these peptides, but an animal hormone profile cannot settle which is safer during months of human use.

7. CJC-1295 and GHRP-2 stacks

CJC-1295 and GHRP-2 act through different receptors involved in GH secretion. This gives researchers a reason to investigate combined stimulation. The single-compound studies above cannot establish an effective blend ratio or a superior muscle-building result.

The product name also needs checking. Teichman and colleagues studied long-acting CJC-1295, reporting a half-life of 5.8–8.1 days. Products sold as “CJC-1295 no DAC” do not have that same long-acting modification. The DAC study cannot supply a dosing interval for a no-DAC/GHRP-2 blend.

When someone starts several compounds together, neither improved sleep nor a new side effect can be confidently assigned to one ingredient. A blend makes administration simpler while leaving that uncertainty unresolved.

8. GHRP-2 half-life, dosage and timing

The Japanese prescribing information, section 16.1, reports an elimination half-life of 0.42–0.69 hours after intravenous administration in 18 healthy adult men. That converts to roughly 25–41 minutes. It describes the studied formulation and route.

Peptide clearance, the GH response and physical adaptation run on different timescales. A half-life graph models declining concentration; it cannot determine the next injection time or predict muscle gain. A nasal spray or subcutaneous product also needs its own absorption data.

There is no validated enhancement dose, cycle length or bedtime schedule. Japan’s diagnostic instructions use fasting conditions to standardize a hormone test. That does not demonstrate that a particular fasting window improves bodybuilding results. Continuous research infusions likewise cannot be converted directly into an occasional injection protocol.

9. GHRP-2 side effects and safety

The pralmorelin diagnostic label lists effects including warmth, stomach rumbling, nausea, low blood pressure and sleepiness. These observations concern clinical testing; they do not quantify the risks of long-term subcutaneous use.

GHRP-2 can affect hormones beyond GH. In the Arvat experiment, researchers measured prolactin, ACTH and cortisol increases in young adults. ACTH stimulates adrenal cortisol production. An acute rise does not establish chronic endocrine disease, but claims of a GH-only effect are inaccurate.

FDA’s safety notice flags potential immune reactions from aggregation and peptide impurities in injectable and nasal compounded GHRP-2. It also notes reports of increased insulin requirements, infection, pancreatitis and deaths in critically ill study participants. FDA explicitly states that causality has not been established. Those reports cannot be presented as proof that GHRP-2 caused each event or used to calculate risk for healthy users.

Long-term metabolic and cancer risks remain inadequately characterized. A supplier’s purity result does not resolve clinical safety, sterility or finished-dose accuracy. Severe abdominal pain, breathing difficulty or fainting after use warrants urgent medical assessment.

10. Approval, tested sport and tracking outcomes

Pralmorelin’s Japanese approval concerns diagnosis of GH deficiency. GHRP-2 has no FDA-approved use. These are different regulatory situations, and neither establishes an approved bodybuilding treatment. FDA’s GHRP-2 safety entry remained listed when checked on September 22, 2026.

WADA’s 2026 Prohibited List names GHRP-2 (pralmorelin) among prohibited GH-releasing peptides. The prohibition applies in and out of competition.

For a clinician reviewing exposure, useful records include the exact product, dates, other medications, appetite changes and symptoms. Keep weight, waist measurements, training performance and laboratory results separate in a tracking log. If hunger increases while strength stays unchanged, both observations belong in the record.

11. GHRP-2 FAQ

• What is GHRP-2 used for?

  GHRP-2 stimulates growth hormone release and has been studied for appetite and endocrine function. Japan uses pralmorelin as a diagnostic agent for growth hormone deficiency. Bodybuilding and anti-aging uses do not have an established benefit or dosing protocol.

• Is GHRP-2 the same as pralmorelin or HGH?

  Pralmorelin is another name for GHRP-2. It stimulates GH secretion; recombinant HGH supplies the hormone directly. GHRP-2 is a peptide, not an anabolic steroid.

• Does GHRP-2 make you hungry?

  Yes, increased food intake has been measured in small controlled human studies. The effect varied with the experimental dose. These meal studies cannot predict an individual's daily calorie intake or long-term weight change.

• Does GHRP-2 build muscle or burn fat?

  There is no dependable healthy-adult trial result specifying muscle gained or fat lost. Increased appetite could make a calorie deficit harder to maintain. A larger GH pulse alone does not establish a physique benefit.

• Does GHRP-2 raise cortisol and prolactin?

  A small human comparison found increases in prolactin, ACTH and cortisol as well as GH. Those acute results do not quantify the frequency of persistent hormone problems during repeated use.

• Does GHRP-2 stop working over time?

  A five-day study in nine healthy men found that GH responses became smaller, although GH release continued. It does not establish when every user develops tolerance or validate a cycling schedule.

• What is GHRP-2's half-life?

  Japanese pralmorelin prescribing information reports an elimination half-life of 0.42–0.69 hours, about 25–41 minutes, after intravenous administration in healthy adult men. That is not a validated interval for subcutaneous injections.

• What is the best GHRP-2 dosage or cycle?

  No validated dose, cycle or fasting schedule exists for healthy-adult physique or recovery goals. Diagnostic administration and research infusions answer different questions from repeated enhancement use.

• Is GHRP-2 better than GHRP-6 or ipamorelin?

  There is no established winner for muscle gain, fat loss or recovery. GHRP-2 has direct human appetite data; claims that it is hunger-free or that receptor selectivity guarantees another peptide's safety overstate the evidence.

• Can GHRP-2 be combined with CJC-1295?

  The compounds stimulate GH through different receptors. That provides a research rationale, but the studies cited here do not establish an effective blend ratio or better physique outcomes from the combination.

• Is GHRP-2 FDA-approved or allowed in tested sport?

  GHRP-2 has no FDA-approved use. FDA flags safety concerns for injectable and nasal compounded products. WADA's 2026 Prohibited List names GHRP-2 (pralmorelin), prohibited in and out of competition.

12. Sources